Diseases, Conditions, Syndromes

No benefit seen with rituximab for chronic fatigue syndrome

(HealthDay)—In patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), B-cell depletion using several infusions of rituximab over 12 months is not associated with clinical improvement, according to a ...

Oncology & Cancer

New leukemia drug is more effective and easier to use

A landmark study co-authored by a Loyola Medicine oncologist has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL).

Neuroscience

Drug may delay MS disability for some

An immune system drug may help prevent or slow complications in a type of multiple sclerosis known as secondary progressive MS, a new study finds.

Neuroscience

Rituximab beneficial in secondary progressive MS

(HealthDay)—For patients with secondary progressive multiple sclerosis (SPMS), treatment with rituximab is associated with a significantly lower Expanded Disability Status Scale (EDSS) score and delayed progression, according ...

Oncology & Cancer

Rituximab plus lenalidomide effective in follicular lymphoma

(HealthDay)—Rituximab plus lenalidomide has similar efficacy to rituximab plus chemotherapy among patients with previously untreated follicular lymphoma, according to a study published in the Sept. 6 issue of the New England ...

Neuroscience

Rituximab tops other disease-modifying tx options in MS

(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published ...

Diseases, Conditions, Syndromes

Rituximab effective for lupus-associated cytopenia

(HealthDay)—Rituximab treatment seems effective for systemic lupus erythematosus (SLE)-associated immune cytopenias, with an overall initial response rate of 86 percent, according to a study published online Dec. 16 in ...

Diseases, Conditions, Syndromes

Study explains why myasthenia patients relapse after treatment

A new Yale-led study helps explain why some myasthenia gravis (MG) patients relapse after initially responding to a drug called rituximab, commonly used to treat the incurable autoimmune disease marked by muscle weakness ...

page 1 from 4